BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Intercell AG Completes Placement of EUR 33.0 Million Senior Convertible Debt Financing


2/23/2011 6:23:53 AM

VIENNA, Feb. 23, 2011 /PRNewswire/ -- Intercell AG (Vienna Stock Exchange, ICLL) ("Intercell" or the "Company") today announced that it successfully placed EUR 33.0m of Senior Unsecured Convertible Notes (the "Notes") in a private placement transaction, which was increased due to investor demand.

The Notes have a conversion price of EUR 11.43 reflecting a premium of 20.0% to the volume weighted average price and of 18.4% to the closing share price of Intercell's shares on February 22, 2011. The Notes bear a fixed rate coupon of 6% per annum which is payable quarterly in arrears. The principal amount will amortize in 11 equal quarterly installments, with a final maturity of March 15, 2014. Principal and interest payments may be paid in cash or, subject to minimum thresholds in trading volumes and values, in freely tradable listed shares of Intercell, at the sole option of the Company. The holders of the Notes may, at their sole option, choose to defer quarterly payments of principal through the final scheduled maturity of the Notes. The original investors in the Notes will have the right to purchase an additional EUR 33.0m of Notes on essentially the same terms as the original issue for a period of 12 months following the closing and an additional EUR 16.5m of Notes at the same coupon and repayment terms, but with a conversion price to be set at a 20% premium to the then current stock price, for a period of 18 months following the closing.

The transaction was subscribed by international institutional investors. The statutory subscription rights of the existing shareholders have been excluded. Closing of the transaction is subject to a confirmatory approval by Intercell's Supervisory Board after the expiry of the 14-day publication period of the Management Board's report on the exclusion of the subscription rights and customary closing conditions. Intercell intends to use the net proceeds for general corporate purposes.

Intercell's CFO, Reinhard Kandera stated: "Intercell is pleased to complete this convertible financing. The offering provides additional financial flexibility to the Company for the advancement of its clinical programs and leading technologies in vaccine and anti-infective antibody innovation as well as regarding important upcoming partnering decisions. The structural features of the Notes enable us to borrow funds at an attractive cost of capital with the flexibility to utilize our stock to satisfy principal and interest payments at our option."

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business, including words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," or similar words. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES